Patent Assignment
Reel/Frame 037821/0938
Corrective Assignment to Correct the Redacted Schedule of the Executed Assignment Document Previously Recorded at Reel: 035384 Frame: 0923. Assignor(S) Hereby Confirms the Assignment.
Recorded: 2016-02-16
Pages: 11
Assignor
ENZON PHARMACEUTICALS, INC.
Executed: 2013-10-24
Assignee
SANTARIS PHARMA A/S
FREMTIDSVEJ 3, HERSHOLM, 2970, DENMARK
Covered Properties
(5)
Lna Antagonists Targeting the Androgen Receptor
Lna Antagonists Targeting the Androgen Receptor
Methods for Treating Androgen Receptor Dependent Disorders Including Cancers
Lna Antagonists Targeting the Androgen Receptor
Application:
13/149,155 →
Publication:
US 2011/0319471
Methods for Treating Androgen Receptor Dependent Disorders Including Cancers
Application:
13/874,238 →
Publication:
US 2014/0031409
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 27, 2009
From: WORM, JESPER
To: SANTARIS PHARMA A/S
Reel/Frame 022322/0932 →
Assignment of Assignor's Interest
Feb 19, 2010
From: SANTARIS PHARMA A/S
To: ENZON PHARMACEUTICALS, INC.; SANTARIS PHARMA A/S
Reel/Frame 023962/0177 →
Assignment of Assignor's Interest
Apr 10, 2015
From: ENZON PHARMACEUTICALS, INC.
To: SANTARIS PHARMA A/S
Reel/Frame 035384/0923 →
Merger and Change of Name
Apr 13, 2015
From: SANTARIS PHARMA A/S; ROCHE INNOVATION CENTER COPENHAGEN A/S
To: ROCHE INNOVATION CENTER COPENHAGEN A/S
Reel/Frame 035421/0435 →